Charles A. Watkins II

Charles advises public and private companies, banks, and non-bank lenders in various debt financing and corporate transactions. His practice focuses on the representation of financial institutions and asset-based lenders, where he advises on structured financings, secured and unsecured credit facilities, syndicated loans, acquisition financing, and convertible bond offerings. Additionally, Charles has general corporate experience advising public companies in securities compliance matters.

Charles’ representative matters include:

• Advising BioXcel Therapeutics in its $260 million strategic financing with Oaktree and Qatar Investment Authority – with up to $135 million in a delayed draw term loan, up to $120 million in capped revenue interest on net sales and up to $5 million in purchase of common stock
• Advising Opthea in its $170 million financing and $90 million private placement and share purchase plan